Veracyte Reports Strong Q4 & Full-Year 2025 Results, Reaffirms Robust 2026 Revenue Guidance

summarizeSummary

Veracyte announced strong Q4 and full-year 2025 financial results, including significant revenue and profit growth, and reiterated its positive 2026 revenue guidance.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  Total revenue increased by 19% to $140.6 million, with testing revenue up 21%. GAAP net income surged 705% to $41.1 million, and Adjusted EBITDA grew 62% to $42.3 million.

• Solid Full-Year 2025 Results

  Total revenue for 2025 grew 16% to $517.1 million, and GAAP net income improved 175% to $66.4 million. Adjusted EBITDA increased 55% to $142.5 million.

• Robust Cash Generation

  The company generated $52.6 million in cash from operations in Q4 and $136.3 million for the full year, ending 2025 with $412.9 million in cash, cash equivalents, and short-term investments.

• Reiterated 2026 Financial Guidance

  Veracyte reaffirmed its 2026 total revenue guidance of $570 million to $582 million, representing 10% to 13% growth, with testing revenue expected to grow 14% to 16%.

auto_awesomeAnalysis

Veracyte delivered an exceptional financial performance for Q4 and full-year 2025, exceeding its preliminary Q4 revenue growth and significantly boosting profitability. The company's GAAP net income surged by 705% in Q4 and 175% for the full year, alongside strong Adjusted EBITDA growth and substantial cash generation. The reaffirmation of solid 2026 revenue guidance, coupled with upcoming product launches like Prosigna LDT and TrueMRD, signals continued positive momentum and strategic expansion. This filing finalizes the preliminary results previously reported and provides comprehensive forward-looking guidance, reinforcing investor confidence in the company's growth trajectory and operational efficiency.